CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
In conclusion, pre-emptive CD19 CAR-T cell treatment is an effective and safe approach and may confer sustained remission in B-ALL patients with chemotherapy-refractory MRD. The trials were registered atwww.chictr.org.cn as ChiCTR-ONN-16009862 (November 14, 2016) and ChiCTR1800015164 (March 11, 2018).
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Leukemia | Statistics